5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
A prescriber-level guide to recognizing, grading, and managing adverse events with siRNA lipid therapeutics, inclisiran, fitusiran, and related agents, covering injection-site reactions, liver effects, bleeding risk, and off-target monitoring.
A complete MD/PharmD-level guide to the siRNA lipid therapeutics drug class, inclisiran prescribing, billing codes, and prior authorization strategies for twice-yearly LDL reduction.
A prescriber-level DDI reference for siRNA lipid therapeutics (inclisiran, vutrisiran, patisiran). Covers mechanism, pharmacokinetics, DDI table, dosing, and monitoring guidance with primary literature citations.
A prescriber-level guide to siRNA lipid-lowering agents, covering inclisiran pharmacology, patient selection, dosing, and how to choose between available agents based on current trial data and guidelines.
Clinician-focused review of siRNA lipid therapeutics (inclisiran) across special populations including renal impairment, hepatic impairment, elderly patients, and pregnancy. Dosing adjustments, monitoring, and evidence gaps.